You just read:

Inovio's dMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies

News provided by

Inovio Pharmaceuticals, Inc.

Jan 15, 2019, 08:00 ET